GIM
BMY icon

Glenmede Investment Management’s Bristol-Myers Squibb BMY Stock Holding History

Glenmede Investment Management’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$48M Buy
1,065,333
+252,666
+31% +$11.8M 0.23% 85
2025
Q2 		$37.6M Buy
+812,667
New +$39.9M 0.19% 103

Other funds holding BMY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Glenmede Investment Management's BMY Position: Q3 2025 in Review

Glenmede Investment Management increased its Bristol-Myers Squibb (BMY) stake by 31% in Q3 2025, buying an estimated $11.8M and bringing the position to 1,065,333 shares worth $48M. The position accounts for 0.23% of the portfolio, ranked #85.

Glenmede Investment Management first reported a position in BMY in Q2 2025 and has held it in 2 quarters since. 2,267 funds tracked by Wall St. Rank hold BMY as of Q3 2025.

  • Glenmede Investment Management held 1,065,333 shares of Bristol-Myers Squibb worth $48M as of Q3 2025.
  • Glenmede Investment Management bought 252,666 Bristol-Myers Squibb shares in Q3 2025, an estimated $11.8M.
  • Bristol-Myers Squibb made up 0.23% of Glenmede Investment Management's portfolio in Q3 2025, its #85 holding.
  • Glenmede Investment Management first reported a position in Bristol-Myers Squibb in Q2 2025 and has held it in 2 quarters since.
  • 2,267 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.